United-Guardian Inc(UG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 12.56 | EPS (ttm) | 0.54 | Insider Own | 35.65% | Shs Outstand | 4.6M | Perf Week | -0.15% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 3.0M | Perf Month | -6.65% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | - | Inst Own | 19.24% | Short Float | 0.26% | Perf Quarter | -6.65% |
| Income | 0.00B | P/S | 2.76 | EPS this Y | - | Inst Trans | -0.39% | Short Ratio | 0.8 | Perf Half Y | -4.26% |
| Sales | 0.01B | P/B | 2.66 | EPS next 5Y | - | ROA | 18.27% | Short Interest | 0.01M | Perf YTD | 9.42% |
| Book/sh | 2.53 | P/C | 3.23 | EPS past 3/5Y | -6.42% -8.62% | ROE | 21.35% | 52W High | -20.24% ($8.45) | Perf Year | -7.04% |
| Cash/sh | 2.09 | P/FCF | 9.11 | Sales past 3/5Y | -6.01% -0.82% | ROIC | 21.2% | 52W Low | 20.89% ($5.58) | Perf 3Y | 9.06% |
| Dividend Est. | $0.55 (8.16%) | EV/EBITDA | 8.72 | EPS Y/Y TTM | -3.58% | Gross Margin | 46.38% | Volatility(W/M) | 2.68% 3.24% | Perf 5Y | -52.5% |
| Dividend TTM | 0.55 | EV/Sales | 1.91 | Sales Y/Y TTM | 3.23% | Oper. Margin | 20.82% | ATR (14) | 0.22 | Perf 10Y | -55% |
| Dividend Ex-Date | 2026/7/28 | Quick Ratio | 6.64 | EPS Q/Q | 16.28% | Profit Margin | 22% | RSI (14) | 39.95 | Recom | - |
| Dividend Gr. 3/5Y | -4.09% -5.11% | Current Ratio | 7.32 | Sales Q/Q | 9.51% | SMA20 | -2.25% ($6.9) | Beta | 0.99 | Target Price | - |
| Payout | 130.92% | Debt/Eq | 0 | Earnings | - | SMA50 | -4.42% ($7.05) | Rel Volume | 1.32 | Prev Close | $6.66 |
| Employees | 25 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -2.98% ($6.95) | Avg Volume(3M) | 0.01M | Price | $6.74 |
| IPO | 1980/3/17 | Option/Short | No/Yes | Trades | 126 | Volume | 12,466 | Change | 1.13% |
United-Guardian is a small specialty chemical company headquartered in Hollywood, New York, USA. It manufactures and sells cosmetic ingredients, pharmaceuticals, medical lubricants, and wellness products from its in-house research laboratory. Its core business is the B2B supply of its flagship "Lubrajel" hydrogel ingredient to global cosmetic and medical device companies.
Over the past 1 year, roughly in the middle
20% below its 1-year high.
Traded more than usual. That is 132% of its average volume.
UG makes money exceptionally well
Of every $100 in sales, $20.82 is kept as operating profit.
Tap to view numbers
Within its industry, it looks cheap
Counting its debt, for $100 of yearly operating cash you would pay $872. Peers typically go for $1,340. Compared with its own 5-year average, it is 17% cheaper now.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -52.5%. The S&P 500 did +69% over the same period.
Tap to view numbers
Dividends are more than it earns
It pays out 131% of what it earns.
Tap to view numbers
Ownership is about average
Institutions hold 19.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
It ranks #25 of 30 in the industry
Based on market cap of $31M.
FAQ
What kind of company is UG?
UG belongs to the Consumer Defensive sector and operates in the Household & Personal Products industry.
What is the market cap of UG?
The market cap of UG is approximately $31M, ranking 5,073 within its sector.
Does UG pay dividends?
UG has a dividend yield of approximately 8.16%, with an annual dividend of $0.55.
What is the P/E ratio of UG?
UG has a P/E ratio of approximately 12.6x, which can be used to assess its valuation relative to the Consumer Defensive sector average.
What is the 52-week high and low for UG?
UG has recorded a 52-week high of $8.45 and a low of $5.58.